Development of a new therapeutic target molecule for schizophrenia from antipsychotics signaling

点击翻译按钮获取中文摘要

We have identified two molecules as downstream substrates for Fyn-mediate anti-psychotic signaling. For one of those molecules, we also determined antipsychotics-mediate phosphorylation sites. Using post-mortem brain samples, we found that the Fyn protein levels are increased in the schizophrenia frontal cortices compared to the controls. Also, the mRNA expression of CADPS2, which is involved in the exocytosis of monoamines, was increased in schizophrenia brains. In the cerebrospinal fluids, the levels of IL-6, which is upstream regulator of Fyn, and the levels of dopamine metabolite, HVA, were increased in schizophrenia. Thus, we have identified a group of molecules involved in antipsychotic signaling and, found that a part of those molecules should be involved in the schizophrenia pathology. Further research is required to clarify whether those molecules could be therapeutic targets for schizophrenia.